• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Will Abiraterone Guidance Data Change Veracyte (VCYT) Stock Narrative

    Simply Wall St·11/02/2026 22:20:44
    Listen to the news
    • Veracyte reported new retrospective data from the Phase III STAMPEDE trial and a 27,000-patient real-world cohort showing its Decipher Prostate Genomic Classifier can predict which clinically very high-risk nonmetastatic prostate cancer patients benefit from adding abiraterone to androgen deprivation therapy.
    • The evidence strengthens Decipher’s high-risk use claims and supports wider testing before treatment intensification decisions, which could influence test volumes, guideline positioning, and payer discussions for Veracyte’s prostate cancer franchise.
    • We will now look at how Veracyte's investment narrative could shift as Decipher’s predictive value for abiraterone benefit gains support.

    Scan other genomics and precision oncology stocks that could see similar treatment-driven demand shifts using our curated list of 33 healthcare AI stocks aligned with healthcare data and AI-enabled diagnostics.

    Veracyte Investment Narrative Recap

    To own Veracyte, you need to believe genomic tests like Decipher and Afirma can keep gaining clinical traction and payer support as evidence stacks up. The STAMPEDE data reinforces Decipher’s role in treatment decisions for very high risk prostate cancer, which supports the idea that test adoption can be tied directly to drug use and guideline inclusion.

    The key near term swing factor is whether higher clinical utility for Decipher translates into sustained volume growth without squeezing pricing. The biggest risk stays the same. Veracyte leans heavily on a few assays, so any reimbursement pushback, competing test, or new technology that undercuts Decipher or Afirma would hit the whole business.

    The most relevant prior development here is the recent incorporation of earlier STAMPEDE Decipher data into the NCCN 2027 prostate cancer guidelines for high and very high risk disease. That guideline presence sits alongside the new predictive evidence and together they may support physicians viewing Decipher less as a “nice to have” prognostic tool and more as a routine part of treatment planning.

    For you as an investor, the link to catalysts is straightforward. Stronger guideline footing and predictive data could support case building with payers, protect pricing against reimbursement pressure, and help Veracyte extend Decipher across more risk groups. The risk is that guideline support alone does not guarantee that payer policies or ordering habits will shift as quickly as the evidence base.

    Veracyte's current analyst narrative points to forecast revenue of US$787.4 million and earnings of US$116.9 million by 2029. That profile lines up with assumed revenue growth of 11.9% per year and an earnings increase of about US$2.4 million from US$114.5 million today.

    Discover how Veracyte's fair value indicates a 19% potential upside to its current price that may not last much longer.

    NasdaqGM:VCYT 1-Year Stock Price Chart
    NasdaqGM:VCYT 1-Year Stock Price Chart

    Exploring Other Perspectives

    One alternative angle you might consider is the bearish worry that Veracyte’s whole genome and GRID data platforms stay expensive to run without turning into meaningful revenue. The most pessimistic analysts were pencilling in 2029 earnings of about US$90.1 million on roughly US$768.8 million of sales before this Decipher news, so their story could shift if perceptions change.

    Explore 3 other Veracyte fair value estimates, including one that suggests it could be worth just $59.73.

    Reach Your Own Conclusion

    Don't just follow the ticker; dig into the data and build a conviction that's truly your own.

    Looking for more Veracyte style investment ideas?

    If the Veracyte story has you thinking about where evidence based growth or resilience could come from next, the Simply Wall St Screener can help you scan for other companies that fit your risk, income, or quality preferences in a structured way.